PMID- 12760798
OWN - NLM
STAT- MEDLINE
DCOM- 20041012
LR  - 20160818
IS  - 0529-5807 (Print)
IS  - 0529-5807 (Linking)
VI  - 32
IP  - 1
DP  - 2003 Feb
TI  - [Loss of p53 gene and amplification of HER-2 oncogene in primary hepatocellular 
      carcinoma and their clinical significance].
PG  - 20-4
AB  - OBJECTIVE: To investigate the deletion of p53 gene and amplification of HER-2 
      oncogene at chromosome 17 in primary hepatocellular carcinoma (HCC) and the 
      clinical significance. METHODS: Interphase dual fluorescence in situ 
      hybridization (FISH) was applied to detect the ratio of the number of p53 gene 
      copy or HER-2 oncogene copy to that of chromosome 17 copy, to determine the p53 
      gene deletion and HER-2 oncogene amplification in nuclei prepared from 42 
      surgical specimens of HCC. Statistical analysis for their clinical significance 
      was performed. RESULTS: Loss of p53 gene and amplification of HER-2 oncogene were 
      detected in 27 (64.3%) and 9 (21.4%) of the 42 HCC respectively including 4 cases 
      with low and 5 with high copy amplification. Six (14.3%) of 42 HCC showed 
      simultaneously p53 gene deletion and HER-2 oncogene amplification. 61.9% (26/42) 
      of HCC were polysomy 17, which correlated positively with p53 gene deletion 
      (chi(2) = 12.286, P < 0.001). No close correlation between p53 gene loss and 
      HER-2 oncogene amplification was found (chi(2) = 0.00, P = 1.00). Loss of p53 
      gene was related to the serum alpha-fetoprotein (AFP) level and the tumor size (P 
      < 0.05). The postoperative 2-year survival rate (18.5%) of HCC patients with p53 
      gene deletion was significantly lower than postoperative 2-year survival rate 
      (60.0%) of those without p53 gene loss (chi(2) = 7.467, P = 0.006). Meanwhile, 
      HER-2 oncogene amplification showed a tendency of correlation with the tumor size 
      (chi(2) = 2.973, P = 0.085), and the postoperative 2-year survival rate (0/9) of 
      HCC patients with HER-2 oncogene amplification was significantly lower than those 
      (42.4%) without HER-2 oncogene amplification (chi(2) = 3.977, P = 0.046). 
      CONCLUSION: There were a high frequency of p53 gene deletion and a low frequency 
      of HER-2 oncogene amplification in primary HCC, which might be involved in 
      initiation and development of a subset of primary HCC.
FAU - Huang, Bi-jun
AU  - Huang BJ
AD  - Department of Etiology, Cancer Institute, Cancer Center, Sun Yat-sen University, 
      Guangzhou 510060, China.
FAU - Zhu, Zhen-yu
AU  - Zhu ZY
FAU - Liang, Qi-wan
AU  - Liang QW
FAU - Fang, Yan
AU  - Fang Y
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Bing Li Xue Za Zhi
JT  - Zhonghua bing li xue za zhi = Chinese journal of pathology
JID - 0005331
RN  - 0 (alpha-Fetoproteins)
SB  - IM
MH  - Adult
MH  - Carcinoma, Hepatocellular/*genetics/pathology
MH  - *Chromosomes, Human, Pair 17
MH  - Female
MH  - Gene Amplification
MH  - Gene Deletion
MH  - *Genes, erbB-2
MH  - *Genes, p53
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Liver Neoplasms/*genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - Polyploidy
MH  - Survival Rate
MH  - alpha-Fetoproteins/metabolism
EDAT- 2003/05/23 05:00
MHDA- 2004/10/13 09:00
CRDT- 2003/05/23 05:00
PHST- 2003/05/23 05:00 [pubmed]
PHST- 2004/10/13 09:00 [medline]
PHST- 2003/05/23 05:00 [entrez]
PST - ppublish
SO  - Zhonghua Bing Li Xue Za Zhi. 2003 Feb;32(1):20-4.